Serum hepatitis B core-related antigen predicts hepatocellular carcinoma in hepatitis B e antigen-negative patients

被引:26
作者
Liang, Lilian Yan [1 ,2 ]
Wong, Vincent Wai-Sun [1 ,2 ,3 ]
Toyoda, Hidenori [4 ]
Tse, Yee-Kit [1 ,2 ]
Yip, Terry Cheuk-Fung [1 ,2 ]
Yuen, Becky Wing-Yan [1 ,2 ]
Tada, Toshifumi [4 ]
Kumada, Takashi [4 ]
Lee, Hye-Won [5 ]
Lui, Grace Chung-Yan [2 ]
Chan, Henry Lik-Yuen [1 ,2 ,3 ]
Wong, Grace Lai-Hung [1 ,2 ,3 ]
机构
[1] Chinese Univ Hong Kong, Inst Digest Dis, Hong Kong, Peoples R China
[2] Chinese Univ Hong Kong, Dept Med & Therapeut, Shatin, 9-F Prince Wales Hosp, Hong Kong, Peoples R China
[3] Chinese Univ Hong Kong, State Key Lab Digest Dis, Hong Kong, Peoples R China
[4] Ogaki Municipal Hosp, Ogaki, Gifu, Japan
[5] Yonsei Univ, Dept Internal Med, Coll Med, Seoul, South Korea
关键词
Hepatitis B core-related antigen; Hepatitis B surface antigen; Hepatocellular carcinoma; Antiviral agents; SURFACE-ANTIGEN; RISK SCORES; ENTECAVIR; DNA; VALIDATION; INFECTION; IMPACT;
D O I
10.1007/s00535-020-01700-z
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background Hepatitis B core-related antigen (HBcrAg) is a novel serum viral marker. Recent studies showed that its level correlates with the risk of hepatocellular carcinoma (HCC) in patients with chronic hepatitis B (CHB). We aimed to evaluate the accuracy of serum HBsAg and HBcrAg levels at baseline to predict HCC. Methods 1400 CHB patients who received nucleos(t)ide analogues (NA) treatment since December 2005 were included. Their stored serum samples at baseline were retrieved to measure HBsAg and HBcrAg levels. The primary endpoint was the cumulative incidence of HCC. Results 85 (6.1%) patients developed HCC during a mean (+/- SD) follow-up duration of 45 +/- 20 months. Serum HBcrAg level above 2.9 log10 U/mL at baseline was an independent factor for HCC in hepatitis B e antigen (HBeAg)-negative patients by multivariable analysis (adjusted hazard ratio 2.13, 95% CI 1.10-4.14,P = 0.025). HBcrAg above 2.9 log(10)U/mL stratified the risk of HCC in HBeAg-negative patients with high PAGE-B score (P = 0.024 by Kaplan-Meier analysis), and possibly in cirrhotic patients (P = 0.08). Serum HBsAg level did not show any correlation with the risk of HCC in all patients or any subgroups. Conclusion Serum HBcrAg level predicts the risk of HCC accurately in NA-treated HBeAg-negative CHB patients.
引用
收藏
页码:899 / 908
页数:10
相关论文
共 38 条
[1]   Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: limited role for risk scores in Caucasians [J].
Arends, Pauline ;
Sonneveld, Milan J. ;
Zoutendijk, Roeland ;
Carey, Ivana ;
Brown, Ashley ;
Fasano, Massimo ;
Mutimer, David ;
Deterding, Katja ;
Reijnders, Jurrien G. P. ;
Oo, Ye ;
Petersen, Joerg ;
van Boemmel, Florian ;
de Knegt, Robert J. ;
Santantonio, Teresa ;
Berg, Thomas ;
Welzel, Tania M. ;
Wedemeyer, Heiner ;
Buti, Maria ;
Pradat, Pierre ;
Zoulim, Fabien ;
Hansen, Bettina ;
Janssen, Harry L. A. .
GUT, 2015, 64 (08) :1289-1295
[2]   Viral Determinants of Hepatitis B Surface Antigen Seroclearance in Hepatitis B e Antigen-Negative Chronic Hepatitis B Patients [J].
Chan, Henry Lik-Yuen ;
Wong, Grace Lai-Hung ;
Tse, Chi-Hang ;
Chan, Hoi-Yun ;
Wong, Vincent Wai-Sun .
JOURNAL OF INFECTIOUS DISEASES, 2011, 204 (03) :408-414
[3]   Infection and Cancer: The Case of Hepatitis B [J].
Chan, Stephen L. ;
Wong, Vincent W. S. ;
Qin, Shukui ;
Chan, Henry L. Y. .
JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (01) :83-90
[4]   Prediction model of hepatocellular carcinoma risk in Asian patients with chronic hepatitis B treated with entecavir [J].
Chen, Chien-Hung ;
Lee, Chuan-Mo ;
Lai, Hsueh-Chou ;
Hu, Tsung-Hui ;
Su, Wen-Pang ;
Lu, Sheng-Nan ;
Lin, Chia-Hsin ;
Hung, Chao-Hung ;
Wang, Jing-Houng ;
Lee, Mei-Hsuan ;
Peng, Cheng-Yuan .
ONCOTARGET, 2017, 8 (54) :92431-92441
[5]   Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level [J].
Chen, CJ ;
Yang, HI ;
Su, J ;
Jen, CL ;
You, SL ;
Lu, SN ;
Huang, GT ;
Iloeje, UH .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 295 (01) :65-73
[6]   The role of quantitative hepatitis B surface antigen revisited [J].
Cornberg, Markus ;
Wong, Vincent Wai-Sun ;
Locarnini, Stephen ;
Brunetto, Maurizia ;
Janssen, Harry L. A. ;
Chan, Henry Lik-Yuen .
JOURNAL OF HEPATOLOGY, 2017, 66 (02) :398-411
[7]   EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection [J].
Lampertico P. ;
Agarwal K. ;
Berg T. ;
Buti M. ;
Janssen H.L.A. ;
Papatheodoridis G. ;
Zoulim F. ;
Tacke F. .
JOURNAL OF HEPATOLOGY, 2017, 67 (02) :370-398
[8]   EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma (vol 69, pg 182, 2018) [J].
Galle, Peter R. ;
Forner, Alejandro ;
Llovet, Josep M. ;
Mazzaferro, Vincenzo ;
Piscaglia, Fabio ;
Raoul, Jean-Luc ;
Schirmacher, Peter ;
Vilgrain, Valerie .
JOURNAL OF HEPATOLOGY, 2019, 70 (04) :817-817
[9]   Impact of hepatitis B core-related antigen on the incidence of hepatocellular carcinoma in patients treated with nucleos(t)ide analogues [J].
Hosaka, Tetsuya ;
Suzuki, Fumitaka ;
Kobayashi, Masahiro ;
Fujiyama, Shunichirou ;
Kawamura, Yusuke ;
Sezaki, Hitomi ;
Akuta, Norio ;
Suzuki, Yoshiyuki ;
Saitoh, Satoshi ;
Arase, Yasuji ;
Ikeda, Kenji ;
Kobayashi, Mariko ;
Kumada, Hiromitsu .
ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 49 (04) :457-471
[10]   New enzyme immunoassay for detection of hepatitis B virus core antigen (HBcAg) and relation between levels of HBcAg and HBV DNA [J].
Kimura, T ;
Rokuhara, A ;
Matsumoto, A ;
Yagi, S ;
Tanaka, E ;
Kiyosawa, K ;
Maki, N .
JOURNAL OF CLINICAL MICROBIOLOGY, 2003, 41 (05) :1901-1906